Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

PTCT

PTC Therapeutics Inc

Mar 31 • 04:00PM ET

50.96

Dollar change -3.28
Percentage change -6.05	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT ALNY BIIB VRTX IONS RARE EXEL ARWR BLUE VYGR

| Held by: VTI IWM VB VXF VBK XBI IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.73	Insider Own	2.60%	Shs Outstand	77.70M	Perf Week	-10.64%
Market Cap	4.02B	Forward P/E	-	EPS next Y	-1.91	Insider Trans	-15.22%	Shs Float	76.82M	Perf Month	-7.78%
Income	-363.30M	PEG	-	EPS next Q	-1.03	Inst Own	97.64%	Short Float	5.60%	Perf Quarter	11.17%
Sales	806.78M	P/S	4.98	EPS this Y	18.35%	Inst Trans	-1.93%	Short Ratio	5.77	Perf Half Y	35.32%
Book/sh	-14.13	P/B	-	EPS next Y	50.54%	ROA	-20.07%	Short Interest	4.30M	Perf Year	73.10%
Cash/sh	14.45	P/C	3.53	EPS next 5Y	-	ROE	-	52W Range	24.00 - 58.38	Perf YTD	12.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.04%	ROI	-	52W High	-12.71%	Beta	0.54
Dividend TTM	-	Quick Ratio	2.31	Sales past 5Y	23.09%	Gross Margin	85.36%	52W Low	112.38%	ATR (14)	2.66
Dividend Ex-Date	-	Current Ratio	2.35	EPS Y/Y TTM	43.51%	Oper. Margin	-18.19%	RSI (14)	40.92	Volatility	5.58% 4.69%
Employees	939	Debt/Eq	-	Sales Y/Y TTM	-13.97%	Profit Margin	-45.03%	Recom	2.27	Target Price	63.57
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	58.64%	Payout	-	Rel Volume	2.54	Prev Close	54.24
Sales Surprise	-8.29%	EPS Surprise	-57.32%	Sales Q/Q	-30.58%	Earnings	Feb 27 AMC	Avg Volume	745.86K	Price	50.96
SMA20	-6.26%	SMA50	-0.12%	SMA200	22.82%	Trades		Volume	1,898,153	Change	-6.05%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral	$41 → $55
Mar-07-25	Initiated	Scotiabank	Sector Perform	$55
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45 → $67
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$39 → $63
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform	$44
Aug-26-24	Resumed	UBS	Buy	$47
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform	$48
Dec-14-22	Initiated	Goldman	Sell	$35
Sep-12-22	Initiated	Jefferies	Buy	$62
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$54
Sep-01-22	Initiated	Citigroup	Buy	$70

Show Previous Ratings

Mar-28-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.05%
09:00AM	PTC Therapeutics Provides Regulatory Update on Translarna (ataluren) in Europe (PR Newswire)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-20-25 08:00AM	PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies (PR Newswire)
Feb-28-25 11:41AM	Q4 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.27%
02:35AM	Loading…
02:35AM	PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... (GuruFocus.com)
Feb-27-25 05:30PM	PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:17PM	PTC Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-26-25 07:21AM	PTC Therapeutics Inc (PTCT) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 09:16AM	Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-20-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	PTC Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-19-25 07:00AM	PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia (PR Newswire)
08:00AM	Loading…
Feb-13-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-04-25 08:21AM	PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald (TipRanks)
05:01AM	PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? (Zacks)
Feb-03-25 03:07PM	Why PTC Therapeutics (PTCT) Stock Is Rallying Today (Insider Monkey) +9.00%
Jan-13-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.09%
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and RandD Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-23-24 08:00AM	PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-24 08:00AM	PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia (PR Newswire)
Dec-17-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
09:34AM	UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
Dec-04-24 07:15AM	PTC Therapeutics price target raised to $71 from $47 at UBS (TipRanks)
Dec-03-24 04:42AM	Novartis and PTC Therapeutics link to develop Huntingtons therapy (Pharmaceutical Technology)
Dec-02-24 04:21PM	PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone (Investor's Business Daily) +18.66%
12:58PM	Loading…
12:58PM	PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program (Benzinga)
12:40PM	PTC Therapeutics Stock Soars on Novartis Licensing Agreement (Investopedia)
11:29AM	Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14% (GuruFocus.com)
07:00AM	PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program (PR Newswire)
05:56AM	Novartis wagers billions of dollars on PTC Huntingtons drug (BioPharma Dive)
Nov-28-24 07:11AM	PTC Therapeutics to sell Priority Review Voucher for $150M (TipRanks)
Nov-27-24 10:12AM	PTC Therapeutics ALS drug fails to meet endpoints as trials shut down (Clinical Trials Arena)
07:51AM	PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs (Benzinga)
07:00AM	PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million (PR Newswire)
05:38AM	Kronos, Idorsia plan layoffs; PTC shelves ALS drug (BioPharma Dive)
Nov-26-24 04:30PM	PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients (PR Newswire) +7.02%
Nov-25-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-14-24 01:46PM	FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain (Benzinga)
10:00AM	FDA grants accelerated approval for PTCs AADC deficiency gene therapy (Pharmaceutical Technology)
06:28AM	PTC wins US approval of gene therapy for fatal enzyme disorder (BioPharma Dive)
Nov-13-24 06:02PM	PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy (PR Newswire)
Nov-08-24 10:05AM	PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Nov-07-24 06:30PM	PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:23PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-06-24 09:15AM	Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics (Zacks) +5.65%
07:11AM	PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 04:30PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Nov-01-24 06:06AM	Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug (BioPharma Dive)
Oct-30-24 07:00AM	PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission (PR Newswire)
Oct-25-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-24-24 07:00AM	PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results (PR Newswire)
Oct-18-24 03:01PM	State Street Corp's Strategic Acquisition in PTC Therapeutics Inc (GuruFocus.com) +5.65%
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
06:30AM	CHMP Maintains Negative Opinion on Translarna Reexamination (PR Newswire)
Oct-17-24 10:01AM	Will PTC Therapeutics (PTCT) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-14-24 04:30PM	PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results (PR Newswire)
Oct-09-24 05:54PM	PTC Therapeutics Inc (PTCT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
03:07PM	PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains? (Zacks)
Oct-08-24 08:00AM	PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program (PR Newswire) +16.52%
Oct-04-24 05:17AM	3 Top Stocks That Could Still Rocket Higher in 2024 (Motley Fool)
Oct-01-24 09:00AM	PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients (PR Newswire)
05:00AM	5 FDA decisions to watch in the fourth quarter (BioPharma Dive)
Sep-26-24 08:00AM	FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program (PR Newswire)
Sep-12-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-28-24 04:30PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-19-24 03:33PM	PTC Therapeutics Stock Earns RS Rating Upgrade To 83 (Investor's Business Daily)
Aug-08-24 05:15PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:09PM	PTC Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-06-24 09:15AM	Unlocking Q2 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jul-30-24 08:00AM	PTC Therapeutics Announces Sepiapterin NDA Submission to FDA (PR Newswire)
Jul-25-24 04:30PM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results (PR Newswire)
10:02AM	Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-01-24 08:00AM	PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug (Zacks)
Jun-28-24 04:08PM	PTC's Journey Of 'Twist And Doubt' Continues With Another Rejection; Shares Tumble (Investor's Business Daily) -11.77%
08:53AM	PTC Therapeutics Tumbles After European Regulators Reject Its Drug Again (Investor's Business Daily)
07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
06:00AM	CHMP Issues Negative Opinion on Translarna Following European Commission Request for Review (PR Newswire)
Jun-24-24 04:44AM	PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock? (Zacks)
Jun-21-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +9.70%
Jun-20-24 08:19AM	FDA lifts hold on PTC Huntingtons disease trial (BioPharma Dive) -6.54%
06:30AM	Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients (PR Newswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-29-24 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conference (PR Newswire)
May-28-24 08:30AM	PTC Therapeutics Announces Validation of Sepiapterin European MAA (PR Newswire)
May-25-24 02:41AM	Insider Sale: Director Jerome Zeldis Sells 20,000 Shares of PTC Therapeutics Inc (PTCT) (GuruFocus.com)
May-21-24 12:26PM	PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug (Zacks)
10:34AM	Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating (MT Newswires)
May-20-24 04:05PM	PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day' (Investor's Business Daily) +21.23%
12:36PM	Raymond James Upgrades PTC Therapeutics to Market Perform From Underperform (MT Newswires)
12:20PM	PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation (PR Newswire)
08:57AM	Sector Update: Health Care (MT Newswires)
08:45AM	PTC Therapeutics Says European Commission Seeking Review of Negative Opinion on Translarna (MT Newswires)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pauwels Eric	CHIEF BUSINESS OFFICER	Mar 17 '25	Sale	56.80	6,762	384,067	72,640	Mar 18 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Mar 14 '25	Sale	55.19	4,458	246,037	79,402	Mar 18 05:20 PM
Okey Stephanie	Director	Mar 13 '25	Sale	54.00	5,000	270,000	8,867	Mar 17 05:20 PM
Pauwels Eric	Officer	Mar 17 '25	Proposed Sale	56.80	6,762	384,064		Mar 17 04:48 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 12 '25	Option Exercise	33.02	15,521	512,503	117,027	Mar 14 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 12 '25	Sale	53.30	15,521	827,233	103,901	Mar 14 05:20 PM
Pauwels Eric	Officer	Mar 14 '25	Proposed Sale	55.19	4,458	246,024		Mar 14 04:24 PM
Okey Stephanie	Director	Mar 13 '25	Proposed Sale	54.00	5,000	270,000		Mar 13 10:23 AM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 10 '25	Option Exercise	31.81	68,039	2,164,193	149,293	Mar 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 11 '25	Option Exercise	33.02	7,381	243,721	109,563	Mar 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 10 '25	Sale	53.09	68,039	3,611,982	103,901	Mar 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 11 '25	Sale	53.02	7,381	391,323	103,901	Mar 12 05:20 PM
Boulding Mark Elliott	Officer	Mar 12 '25	Proposed Sale	53.30	15,521	827,199		Mar 12 04:33 PM
Boulding Mark Elliott	Officer	Mar 11 '25	Proposed Sale	53.02	7,381	391,321		Mar 11 04:21 PM
Boulding Mark Elliott	Officer	Mar 10 '25	Proposed Sale	53.09	68,039	3,612,075		Mar 10 04:28 PM
Jacobson Allan Steven	Director	Mar 04 '25	Sale	51.52	1,230	63,370	19,118	Mar 06 05:20 PM
Jacobson Allan Steven	Director	Mar 04 '25	Proposed Sale	51.52	1,230	63,365		Mar 04 12:35 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Feb 19 '25	Sale	50.10	879	44,034	63,442	Feb 21 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Feb 20 '25	Sale	50.12	878	44,009	62,564	Feb 21 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Feb 19 '25	Sale	50.10	1,168	58,512	75,603	Feb 21 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Feb 20 '25	Sale	50.12	1,167	58,495	74,436	Feb 21 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Feb 20 '25	Sale	50.12	1,567	78,544	83,860	Feb 21 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	50.10	1,378	69,032	85,427	Feb 21 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Feb 20 '25	Sale	50.12	3,895	195,233	276,038	Feb 21 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	50.10	3,897	195,224	279,933	Feb 21 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Feb 20 '25	Sale	50.12	962	48,219	76,894	Feb 21 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Feb 19 '25	Sale	50.10	795	39,826	77,856	Feb 21 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Feb 20 '25	Sale	50.12	1,614	80,900	103,901	Feb 21 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Feb 19 '25	Sale	50.10	1,333	66,778	105,515	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 20 '25	Sale	50.12	1,578	79,096	100,353	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 19 '25	Sale	50.10	1,300	65,125	101,931	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 20 '25	Sale	50.12	34	1,704	5,907	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 19 '25	Sale	50.10	34	1,703	5,941	Feb 21 05:20 PM
Almstead Neil Gregory	Officer	Feb 20 '25	Proposed Sale	50.12	1,578	79,096		Feb 20 04:47 PM
Almstead Neil Gregory	Member of immediate family of	Feb 20 '25	Proposed Sale	50.12	34	1,704		Feb 20 04:33 PM
Boulding Mark Elliott	Officer	Feb 20 '25	Proposed Sale	50.12	1,614	80,900		Feb 20 04:32 PM
Utter Christine Marie	Officer	Feb 20 '25	Proposed Sale	50.12	878	44,009		Feb 20 04:21 PM
Klein Matthew B.	Officer	Feb 20 '25	Proposed Sale	50.12	3,895	195,233		Feb 20 04:20 PM
Golden Lee Scott	Officer	Feb 20 '25	Proposed Sale	50.12	962	48,219		Feb 20 04:18 PM
Gravier Pierre	Officer	Feb 20 '25	Proposed Sale	50.12	1,167	58,495		Feb 20 04:17 PM
Pauwels Eric	Officer	Feb 20 '25	Proposed Sale	50.12	1,567	78,544		Feb 20 04:10 PM
Almstead Neil Gregory	Member of immediate family of	Feb 19 '25	Proposed Sale	50.10	34	1,703		Feb 19 04:36 PM
Almstead Neil Gregory	Officer	Feb 19 '25	Proposed Sale	50.10	1,300	65,125		Feb 19 04:34 PM
Utter Christine Marie	Officer	Feb 19 '25	Proposed Sale	50.10	879	44,035		Feb 19 04:27 PM
Gravier Pierre	Officer	Feb 19 '25	Proposed Sale	50.10	1,168	58,513		Feb 19 04:25 PM
Boulding Mark Elliott	Officer	Feb 19 '25	Proposed Sale	50.10	1,333	66,778		Feb 19 04:18 PM
Klein Matthew B.	Officer	Feb 19 '25	Proposed Sale	50.10	3,897	195,226		Feb 19 04:18 PM
Golden Lee Scott	Officer	Feb 19 '25	Proposed Sale	50.10	795	39,827		Feb 19 04:13 PM
Pauwels Eric	Officer	Feb 19 '25	Proposed Sale	50.10	1,378	69,033		Feb 19 04:11 PM
Bell William F. Jr.	Former Director	Feb 03 '25	Proposed Sale	50.00	10,556	527,800		Feb 03 02:14 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 08 '25	Sale	44.50	1,662	73,959	64,321	Jan 10 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 07 '25	Sale	45.34	1,291	58,534	65,983	Jan 10 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Jan 08 '25	Sale	44.50	2,136	95,052	86,805	Jan 10 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	45.34	1,599	72,499	88,941	Jan 10 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 08 '25	Sale	44.50	2,402	106,889	283,830	Jan 10 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	45.34	2,142	97,118	286,232	Jan 10 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 08 '25	Sale	44.50	1,198	53,311	78,651	Jan 10 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 07 '25	Sale	45.34	810	36,725	79,849	Jan 10 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 08 '25	Sale	44.50	1,998	88,911	106,848	Jan 10 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '25	Sale	45.34	1,543	69,960	108,846	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '25	Sale	44.50	1,552	69,064	103,231	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '25	Sale	45.34	1,265	57,355	104,783	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '25	Sale	44.50	107	4,762	5,975	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '25	Sale	45.34	55	2,494	6,082	Jan 10 05:20 PM
Bell William F. Jr.	Former Director	Jan 10 '25	Proposed Sale	44.57	6,666	297,104		Jan 10 04:44 PM
Almstead Zheng Yang	Member of immediate family of	Jan 08 '25	Proposed Sale	44.50	107	4,761		Jan 08 05:29 PM
Golden Lee Scott	Officer	Jan 08 '25	Proposed Sale	44.50	1,198	53,311		Jan 08 05:19 PM
Almstead Neil Gregory	Officer	Jan 08 '25	Proposed Sale	44.50	1,552	69,064		Jan 08 05:18 PM
Pauwels Eric	Officer	Jan 08 '25	Proposed Sale	44.50	2,136	95,052		Jan 08 05:06 PM
Klein Matthew B.	Officer	Jan 08 '25	Proposed Sale	44.50	2,402	106,889		Jan 08 05:01 PM
Utter Christine Marie	Officer	Jan 08 '25	Proposed Sale	44.50	1,662	73,959		Jan 08 04:51 PM
Boulding Mark Elliott	Officer	Jan 08 '25	Proposed Sale	44.50	1,998	88,911		Jan 08 04:46 PM
Golden Lee Scott	Officer	Jan 07 '25	Proposed Sale	45.34	810	36,723		Jan 07 04:42 PM
Boulding Mark Elliott	Officer	Jan 07 '25	Proposed Sale	45.34	1,543	69,956		Jan 07 04:38 PM
Klein Matthew B.	Officer	Jan 07 '25	Proposed Sale	45.34	2,142	97,113		Jan 07 04:31 PM
Pauwels Eric	Officer	Jan 07 '25	Proposed Sale	45.34	1,599	72,495		Jan 07 04:31 PM
Almstead Neil Gregory	Officer	Jan 07 '25	Proposed Sale	45.34	1,265	57,352		Jan 07 04:24 PM
Almstead Zheng Yang	Member of immediate family of	Jan 07 '25	Proposed Sale	45.34	55	2,494		Jan 07 04:24 PM
Utter Christine Marie	Officer	Jan 07 '25	Proposed Sale	45.34	1,291	58,531		Jan 07 04:13 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 31 '24	Sale	45.16	8,279	373,880	217,528	Jan 03 05:21 PM
Klein Matthew B.	Director	Dec 31 '24	Proposed Sale	45.16	8,279	373,876		Dec 31 03:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Option Exercise	51.00	69,550	3,547,050	153,158	Dec 04 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Option Exercise	51.00	2,060	105,060	6,636	Dec 04 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Sale	52.06	69,550	3,620,895	86,202	Dec 04 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Sale	51.97	2,060	107,063	4,576	Dec 04 05:20 PM
ZELDIS JEROME B	Director	Dec 02 '24	Option Exercise	40.93	24,000	982,320	26,500	Dec 04 05:20 PM
ZELDIS JEROME B	Director	Dec 02 '24	Sale	51.50	24,000	1,235,897	14,500	Dec 04 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Dec 02 '24	Option Exercise	51.00	17,800	907,800	67,123	Dec 04 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Dec 02 '24	Sale	51.77	17,800	921,585	52,428	Dec 04 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Dec 02 '24	Option Exercise	51.00	85,600	4,365,600	176,029	Dec 04 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Dec 03 '24	Option Exercise	33.02	10,308	340,370	100,109	Dec 04 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Dec 02 '24	Sale	52.26	85,600	4,473,280	92,389	Dec 04 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Dec 03 '24	Sale	53.26	10,308	549,055	92,389	Dec 04 05:20 PM
Boulding Mark Elliott	Officer	Dec 03 '24	Proposed Sale	53.26	10,308	549,041		Dec 03 04:52 PM
Almstead Zheng Yang	Member of immediate family of	Dec 02 '24	Proposed Sale	51.98	2,060	107,070		Dec 02 05:16 PM
Almstead Neil Gregory	Officer	Dec 02 '24	Proposed Sale	52.06	69,550	3,620,604		Dec 02 04:48 PM
Utter Christine Marie	Officer	Dec 02 '24	Proposed Sale	51.77	17,800	921,544		Dec 02 04:37 PM
ZELDIS JEROME B	Director	Dec 02 '24	Proposed Sale	51.50	24,000	1,235,914		Dec 02 04:31 PM
Boulding Mark Elliott	Officer	Dec 02 '24	Proposed Sale	52.26	85,600	4,473,211		Dec 02 04:26 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Jul 16 '24	Sale	34.02	2,269	77,200	53,531	Jul 18 05:20 PM

Dollar change -1.19
Percentage change -3.43	%

CRNX Crinetics Pharmaceuticals Inc daily Stock Chart

Peers: NBIX LLY PFE NVS BMRN VRTX REGN SNY MRK BMY

| Held by: VTI IWM VB VXF VBK XBI IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.70	Insider Own	6.91%	Shs Outstand	92.93M	Perf Week	-6.68%
Market Cap	3.12B	Forward P/E	-	EPS next Y	-4.38	Insider Trans	-1.57%	Shs Float	86.62M	Perf Month	-6.26%
Income	-298.41M	PEG	-	EPS next Q	-0.94	Inst Own	104.19%	Short Float	8.97%	Perf Quarter	-37.80%
Sales	0.00M	P/S	-	EPS this Y	-10.98%	Inst Trans	14.74%	Short Ratio	7.85	Perf Half Y	-33.69%
Book/sh	14.26	P/B	2.35	EPS next Y	-7.07%	ROA	-25.27%	Short Interest	7.77M	Perf Year	-24.51%
Cash/sh	14.56	P/C	2.30	EPS next 5Y	3.49%	ROE	-32.02%	52W Range	31.84 - 62.53	Perf YTD	-34.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.11%	ROI	-21.79%	52W High	-46.36%	Beta	0.36
Dividend TTM	-	Quick Ratio	23.04	Sales past 5Y	50.01%	Gross Margin	-	52W Low	5.34%	ATR (14)	1.69
Dividend Ex-Date	-	Current Ratio	23.04	EPS Y/Y TTM	-0.12%	Oper. Margin	-	RSI (14)	41.58	Volatility	5.48% 4.66%
Employees	437	Debt/Eq	0.04	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.18	Target Price	74.33
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	1.58%	Payout	-	Rel Volume	2.45	Prev Close	34.73
Sales Surprise	-100.00%	EPS Surprise	0.69%	Sales Q/Q	-	Earnings	Feb 27 AMC	Avg Volume	990.42K	Price	33.54
SMA20	-2.76%	SMA50	-6.80%	SMA200	-30.57%	Trades		Volume	2,425,830	Change	-3.43%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-25	Initiated	Stifel	Buy	$60
Feb-11-25	Initiated	TD Cowen	Buy
Feb-04-25	Initiated	Wolfe Research	Peer Perform
Jan-22-25	Upgrade	Jefferies	Hold → Buy	$55
Mar-06-24	Initiated	Citigroup	Buy	$68
Jan-16-24	Initiated	Morgan Stanley	Overweight	$50
Dec-21-23	Initiated	Jefferies	Hold	$35
Nov-20-23	Resumed	JP Morgan	Overweight	$35
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$52 → $50
Aug-31-23	Initiated	Oppenheimer	Outperform	$40
Apr-24-23	Initiated	Piper Sandler	Overweight	$56
Mar-30-23	Initiated	Robert W. Baird	Outperform	$48
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$43
Nov-23-21	Initiated	Evercore ISI	Outperform	$68
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight	$28
Dec-23-19	Initiated	ROTH Capital	Buy	$37
Feb-14-19	Initiated	H.C. Wainwright	Buy	$35
Aug-13-18	Initiated	Piper Jaffray	Overweight	$40
Aug-13-18	Initiated	Leerink Partners	Outperform	$43
Aug-13-18	Initiated	JP Morgan	Neutral	$29

Show Previous Ratings

Mar-27-25 04:05PM	Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly (GlobeNewswire)
Mar-10-25 04:36PM	Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +7.74%
03:24PM	Is Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts? (Insider Monkey)
Feb-26-25 07:26AM	What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q4 2024 Earnings (GuruFocus.com)
08:30AM	Loading…
Feb-24-25 08:30AM	Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer (GlobeNewswire) -7.58%
Feb-20-25 04:05PM	Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences (GlobeNewswire)
Feb-10-25 04:44PM	Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-25 04:35PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-05-25 04:57PM	Crinetics Pharmaceuticals, Inc. (CRNX): One of Januarys Biggest Losers (Insider Monkey)
Jan-29-25 05:37PM	What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)? (Insider Monkey)
Jan-21-25 04:10PM	Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-17-25 11:12AM	Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-10-25 05:15PM	Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -16.31%
07:00AM	Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
08:00AM	Loading…
Jan-06-25 08:00AM	Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.00%
Dec-16-24 08:00AM	Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer (GlobeNewswire)
Dec-10-24 08:44PM	Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.21%
06:22AM	FDA accepts Crinetics Pharmaceuticals' NDA for acromegaly treatment therapy (Pharmaceutical Business Review)
Dec-09-24 08:00AM	Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly (GlobeNewswire)
Nov-15-24 09:00AM	Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences (GlobeNewswire) -8.28%
Nov-14-24 04:05PM	UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
Nov-13-24 02:18AM	Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 04:07PM	Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 04:05PM	Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-17-24 03:09PM	State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals (GuruFocus.com)
Oct-16-24 08:00AM	Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-10-24 04:40PM	Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
05:56PM	Loading…
Oct-09-24 05:56PM	Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-08-24 11:55PM	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
04:01PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Sep-26-24 04:05PM	Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly (GlobeNewswire)
Sep-12-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com) +5.02%
Sep-10-24 04:40PM	Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 04:05PM	Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 07:01PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
Aug-14-24 07:02PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
Aug-12-24 04:05PM	Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 09:57PM	CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace) +5.05% -6.11%
06:00PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges (GlobeNewswire)
Aug-01-24 10:01AM	Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-26-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com)
Jul-18-24 04:05PM	Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-12-24 07:01PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com)
Jul-10-24 07:29PM	Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.33%
Jun-26-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com) -5.97%
02:11PM	7 Biotech Stocks to Boost Your Portfolio to Peak Health (InvestorPlace)
Jun-18-24 04:30PM	EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year 2024 Pacific Southwest Award Winner (GlobeNewswire)
Jun-12-24 02:38AM	Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ... (GuruFocus.com) +6.60%
Jun-10-24 06:35PM	Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 12:16PM	Crinetics Unveils 'Stunning' Results In Highly Anticipated Study (Investor's Business Daily)
12:00PM	Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly (GlobeNewswire)
12:00PM	Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS) (GlobeNewswire)
May-31-24 02:46AM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
May-30-24 04:05PM	Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
May-22-24 08:00AM	Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts (GlobeNewswire)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-13-24 10:53AM	Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 05:38PM	Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:03PM	Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing (MT Newswires)
12:47PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results (GuruFocus.com)
May-09-24 08:55PM	CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:35PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:03PM	Crinetics Pharmaceuticals Q1 Net Loss Widens (MT Newswires)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 04:05PM	Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 (GlobeNewswire) +6.78%
May-07-24 08:55AM	Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating (MT Newswires)
May-02-24 04:05PM	Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-11-24 04:05PM	Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.16%
Mar-28-24 08:10AM	Insiders Are Dumping These 5 Healthcare Stocks (Insider Monkey) +5.36%
Mar-26-24 07:01PM	Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-22-24 07:02PM	Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ... (GuruFocus.com)
07:02PM	Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-21-24 02:32AM	Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares (GuruFocus.com)
Mar-20-24 11:46AM	Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals (Zacks)
05:14AM	Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar? (Zacks)
Mar-19-24 04:48PM	Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why (Benzinga) +19.11%
04:03PM	Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win (Investor's Business Daily)
08:08AM	Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win (Investor's Business Daily)
06:16AM	UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study (Reuters)
06:08AM	Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study (Reuters)
06:00AM	Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients (GlobeNewswire)
Mar-12-24 04:05PM	Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome (GlobeNewswire)
Mar-11-24 04:05PM	Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 08:57AM	Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.43%
Feb-28-24 04:36PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Increased R&D Investment Amidst Net Loss ... (GuruFocus.com) +5.66%
04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement (GlobeNewswire)
Feb-15-24 03:14AM	Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc (GuruFocus.com)
Feb-14-24 04:05PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-12-24 04:05PM	Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.42%
Jan-26-24 11:01PM	Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Company Shares (GuruFocus.com)
Jan-13-24 05:03AM	Crinetics Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-10-24 04:33PM	Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pizzuti Dana	Chief Med and Dev Officer	Mar 19 '25	Sale	34.20	2,515	86,021	72,233	Mar 21 06:34 PM
Knight Jeff E.	Chief Operating Officer	Mar 19 '25	Sale	34.20	7,162	244,964	87,491	Mar 21 06:33 PM
Betz Stephen F.	Chief Scientific Officer	Mar 19 '25	Sale	34.20	5,770	197,353	108,588	Mar 21 06:32 PM
Struthers Richard Scott	President & CEO	Mar 19 '25	Sale	34.20	17,338	593,017	329,147	Mar 21 06:31 PM
Pizzuti Dana	Chief Med and Dev Officer	Feb 03 '25	Option Exercise	16.89	5,000	84,450	36,748	Feb 05 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Feb 03 '25	Sale	39.07	5,000	195,350	31,748	Feb 05 04:30 PM
DANA J PIZZUTI	Officer	Feb 03 '25	Proposed Sale	39.07	5,000	195,372		Feb 03 04:11 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '25	Option Exercise	16.89	15,000	253,350	44,248	Jan 07 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 07 '25	Option Exercise	19.64	2,500	49,100	31,748	Jan 07 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '25	Sale	52.09	15,000	781,350	29,248	Jan 07 04:30 PM
DANA J PIZZUTI	Officer	Jan 03 '25	Proposed Sale	52.09	15,000	781,323		Jan 03 04:12 PM
Betz Stephen F.	Chief Scientific Officer	Dec 16 '24	Option Exercise	1.91	2,331	4,452	71,358	Dec 18 04:30 PM
Struthers Richard Scott	President & CEO	Dec 02 '24	Sale	57.57	10,000	575,700	100,000	Dec 04 04:30 PM
Struthers Richard Scott	Officer	Dec 02 '24	Proposed Sale	57.27	10,000	572,700		Dec 02 04:06 PM
Knight Jeff E.	Chief Operating Officer	Nov 22 '24	Sale	56.52	501	28,317	51,653	Nov 26 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Oct 03 '24	Option Exercise	16.89	14,375	242,794	42,882	Oct 07 07:55 AM
Pizzuti Dana	Chief Med and Dev Officer	Oct 03 '24	Sale	54.63	14,375	785,306	28,507	Oct 07 07:55 AM
DANA J PIZZUTI	Officer	Oct 03 '24	Proposed Sale	54.63	14,375	785,322		Oct 03 04:08 PM
Wilson Marc	CFO	Sep 26 '24	Option Exercise	15.29	25,000	382,250	136,092	Sep 30 05:01 PM
Wilson Marc	CFO	Sep 26 '24	Sale	51.11	25,000	1,277,750	111,092	Sep 30 05:01 PM
MARC WILSON	Officer	Sep 26 '24	Proposed Sale	51.10	25,000	1,277,625		Sep 26 04:06 PM
Betz Stephen F.	Chief Scientific Officer	Sep 10 '24	Sale	51.50	1,035	53,302	68,576	Sep 12 04:30 PM
Betz Stephen F.	Officer	Sep 10 '24	Proposed Sale	51.50	1,035	53,301		Sep 10 12:11 PM
Betz Stephen F.	Chief Scientific Officer	Aug 26 '24	Sale	53.19	3,000	159,570	69,611	Aug 28 04:31 PM
Betz Stephen F.	Officer	Aug 26 '24	Proposed Sale	53.19	3,000	159,570		Aug 26 01:16 PM
Betz Stephen F.	Chief Scientific Officer	Aug 12 '24	Sale	47.68	3,000	143,040	72,611	Aug 14 04:30 PM
Betz Stephen F.	Officer	Aug 12 '24	Proposed Sale	47.68	3,000	143,050		Aug 12 11:35 AM
Betz Stephen F.	Chief Scientific Officer	Jul 25 '24	Sale	53.43	3,000	160,290	75,611	Jul 26 04:38 PM
Wilson Marc	CFO	Jul 25 '24	Option Exercise	9.28	19,056	176,840	130,148	Jul 26 04:24 PM
Wilson Marc	CFO	Jul 25 '24	Sale	53.88	19,056	1,026,737	111,092	Jul 26 04:24 PM
Knight Jeff E.	Chief Operating Officer	Jul 15 '24	Option Exercise	22.59	26,073	589,116	78,653	Jul 17 05:35 PM
Knight Jeff E.	Chief Operating Officer	Jul 15 '24	Sale	55.00	27,000	1,485,000	51,653	Jul 17 05:35 PM
Wilson Marc	CFO	Jul 15 '24	Option Exercise	20.02	25,000	500,500	136,092	Jul 17 05:14 PM
Wilson Marc	CFO	Jul 15 '24	Sale	55.00	25,000	1,375,000	111,092	Jul 17 05:14 PM
Betz Stephen F.	Chief Scientific Officer	Jul 10 '24	Sale	48.55	3,000	145,650	78,611	Jul 12 04:30 PM
Hassard James	Chief Commercial Officer	Jul 05 '24	Option Exercise	19.73	15,000	295,950	44,259	Jul 09 06:04 PM
Hassard James	Chief Commercial Officer	Jul 05 '24	Sale	44.08	15,000	661,200	29,259	Jul 09 06:04 PM
Pizzuti Dana	Chief Med and Dev Officer	Jul 03 '24	Option Exercise	16.89	14,375	242,794	42,882	Jul 05 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Jul 03 '24	Sale	44.87	14,375	645,006	28,507	Jul 05 04:30 PM
Wilson Marc	CFO	Jun 28 '24	Option Exercise	9.28	32,129	298,157	143,221	Jul 02 04:32 PM
Wilson Marc	CFO	Jun 28 '24	Sale	43.61	32,129	1,401,146	111,092	Jul 02 04:32 PM
Knight Jeff E.	Chief Operating Officer	Jun 26 '24	Sale	44.38	956	42,427	52,580	Jun 28 05:31 PM
Betz Stephen F.	Chief Scientific Officer	Jun 25 '24	Sale	45.37	3,000	136,110	80,643	Jun 26 04:32 PM
Pizzuti Dana	Chief Med and Dev Officer	Jun 24 '24	Option Exercise	16.89	9,500	160,455	37,286	Jun 25 05:03 PM
Pizzuti Dana	Chief Med and Dev Officer	Jun 24 '24	Sale	45.73	9,500	434,435	27,786	Jun 25 05:03 PM
Hassard James	Chief Commercial Officer	Jun 21 '24	Option Exercise	19.73	15,000	295,950	44,259	Jun 24 05:08 PM
Hassard James	Chief Commercial Officer	Jun 21 '24	Sale	44.66	15,000	669,900	29,259	Jun 24 05:08 PM
Betz Stephen F.	Chief Scientific Officer	Jun 10 '24	Sale	43.86	3,000	131,580	83,643	Jun 11 04:35 PM
Betz Stephen F.	Chief Scientific Officer	May 28 '24	Sale	47.49	3,000	142,470	86,643	May 30 04:28 PM
Betz Stephen F.	Chief Scientific Officer	May 10 '24	Sale	49.43	3,000	148,290	89,643	May 14 06:29 PM
Struthers Richard Scott	President & CEO	May 08 '24	Option Exercise	9.28	107,448	997,117	364,933	May 10 04:57 PM
Struthers Richard Scott	President & CEO	May 08 '24	Sale	49.40	107,448	5,307,931	257,485	May 10 04:57 PM
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Option Exercise	16.89	14,375	242,794	42,161	Apr 17 04:36 PM
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Sale	44.47	14,375	639,256	27,786	Apr 17 04:36 PM
Struthers Richard Scott	President & CEO	Apr 15 '24	Option Exercise	1.91	20,000	38,200	257,835	Apr 17 04:30 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Option Exercise	9.28	40,951	380,025	278,786	Apr 08 05:09 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Sale	49.17	40,951	2,013,561	237,835	Apr 08 05:09 PM

PTCT

PTC Therapeutics Inc

CRNX

Crinetics Pharmaceuticals Inc

Upgrade your FINVIZ experience